Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,276 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
Business Wire (May 14, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (May 14, 2013)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, August 13, 2012, 11:04 AM Teva Pharmaceutical (TEVA -0.4%) says the FDA has accepted for filing its New Drug Application for Quartette, the first ascending-dose, extended regimen oral contraceptive. The submission was based on its successful clinical development program including results from Phase I, Phase II, and Phase III trials designed to evaluate the drugs safety and efficacy. 3 Comments [Healthcare]
- Friday, August 10, 2012, 12:30 PM Mylan's (MYL +0.5%) subsidiary, Mylan Pharmaceuticals, has received final FDA approval for its Modafinil Tablets, the generic version of Teva's (TEVA +0.2%) Provigil Tablets. The drug is designed to improve wakefulness in adult patients with narcolepsy, obstructive sleep apnea and shift work disorder. Comment! [Healthcare]
- Wednesday, August 8, 2012, 9:41 AM Teva (TEVA) and Active Biotech are set to initiate the third Phase III trial of their oral Laquinimod treatment for relapsing remitting multiple sclerosis. Two previous trials have produced positive results. Teva also nominates former Bank Leumi CEO Galia Maor as a director. 3 Comments [Healthcare]
- Monday, August 6, 2012, 4:00 AM Teva (TEVA) has received a subpoena from the SEC over its compliance with U.S. anti foreign bribery laws in Latin America, the company said in a regulatory filing last week. A Reuters investigation has found that eight of the world's top 10 drug firms have warned of potential expenses connected to possible corruption overseas. 2 Comments [Healthcare, Top Stories]
- Friday, August 3, 2012, 3:33 PM The FDA approves the first generic versions of Singulair for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies. Endo Pharmaceuticals (ENDP +3.2%), Mylan (MYL +4.2%) and Teva Pharmaceuticals (TEVA -0.6%) have all been given the go-ahead. Comment! [Healthcare]
- Thursday, August 2, 2012, 8:03 AM More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four new generic drugs in the U.S. and an increase in sales of branded treatments. Affirms FY outlook for adjusted EPS of $5.30-$5.40 vs. consensus of $5.37 and revenue of $20-$21B vs. $20.58B. U.S. sales +28% to $2.5B, European sales unchanged at $1.5B. Comment! [Earnings, Healthcare]
- Thursday, August 2, 2012, 7:08 AM Teva Pharmaceutical Industries (TEVA): Q2 EPS of $1.28 in-line. Revenue of $5.0B (+19% Y/Y) misses by $80M. (PR) 3 Comments [Earnings, Healthcare]
- Thursday, August 2, 2012, 12:05 AM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Wednesday, August 1, 2012, 5:30 PM Notable earnings before Thursday’s open: AEE, APA, ARIA, BDX, CAH, CI, CNP, DNR, DTV, DUK, ENB, GM, INCY, K, MFA, NNN, OCN, PGN, PH, PRX, PWR, PXP, RDC, SBH, SE, SEE, SHO, SNE, SRE, TDC, TE, TEVA, TIE, TWC, UPL, VIAB, VRX, WNR, XEL Comment! [Earnings]
- Monday, July 30, 2012, 6:12 AM EU competition authorities charge Teva (TEVA), France's Servier, Mylan Labs (MYL) and three other companies with blocking generic perindopril drugs from entering the market. Perindopril is used to treat hypertension, and to help prevent problems after heart attacks and procedures. (PR) Comment! [Healthcare]
- Tuesday, July 3, 2012, 11:24 AM The FTC has approved an amended final order settling charges that Teva's (TEVA +1.3%) proposed acquisition of Cephalon would have been anti-competitive for several generic drugs. The order requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals (PRX -0.6%), and allow PRX to sell a generic version of Cephalon's narcolepsy drug Provigil in 2012. Comment! [Healthcare, Global & FX]
- Tuesday, June 26, 2012, 3:31 PM Morgan Stanley says Street estimates are too high for Teva (TEVA -0.8%), and not taking into consideration that copaxone will be filed as a new drug application as apposed to a line extension. The firm expects the FDA to require two phase III trials and notes it does not have a special protocol assessment. 2 Comments [Healthcare]
- Monday, June 25, 2012, 2:04 PM The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL. Comment! [Healthcare, On the Move]
- Monday, June 25, 2012, 1:00 PM Momenta Pharmaceuticals (MNTA -19%) gets slammed today after this weekend's unfavorable ruling against the company in the Copaxone patent litigation brought against the company by Teva (TEVA +5.6%). Oppenheimer says the stock still has compelling long-term value , despite pressure over the near-term. Comment! [Healthcare, On the Move]
-
Monday, June 25, 2012, 9:06 AM
Premarket gainers: LXRX +8%. TEVA +7%. QSFT +6%.
Losers: VTUS -53%. MNTA -23%. SHPGY -12%. CEL -7%. ALU -6%. ARNA -6%. NOK -5%. ING -5%. Comment! [On the Move] - Sunday, June 24, 2012, 9:07 AM Teva Pharmaceutical (TEVA) is +10.5% in Tel Aviv following the favorable ruling on its Copaxone patent in a case against Momenta (MNTA) and Mylan (MYL). While industry watchers had assumed Teva would prevail, with ~35% of its EPS at risk, a hearty sigh of relief isn't surprising. 11 Comments [Top Stories, On the Move, Healthcare]
-
Daniel Shvartsman
$TEVA wins Copaxone trial, up almost 7% AH. I'm bummed it never dropped to my limit orders at 37.5. Weird to drop good news late on Friday. - View all 1 replies
-
Energysystems: Hopefully it'll continue up a bit, looking to lighten up my position.
-
Saibus Research
How to position your exposure to healthcare: Teva Pharma http://bit.ly/LGlm0H $TEVA $TMO - View all 0 replies
-
The Oxen Group
$TEVA has continued to weaken despite recent strength in the market. Death cross forming soon 40/42.50 Bear Call Spread http://stks.co/g0aM - View all 0 replies
-
- View all 2 replies
-
losbronces: Court ruled for Pronova (PRON.OS, PVNAY), regarding patents for Lovaza against PRX and TEVA. -
Mercy Jimenez: thanks losbronces; TEVA =hands full; also saw FDA Warning About a Fake Version Of Teva's ADHD Drug Adderall http://bit.ly/KFik9H
-
Mercy Jimenez
Sold back out TEVA addition from Fri; premarket action @$38 + continued high selling ratio does not look healthy; will add back on drops. - View all 6 replies
-
-
-
- View all 3 replies
-
-
Mathieu Malecot: i am not long MSFT. long NATDF, NOK, INTC and AXPW. looking at TEVA/ MSTF and picked up some miners for the shorter term.
-
- View all 0 replies
-
- View all 0 replies
-
Brad Prigmore
PPG and TEVA killing it the last two days. Love being ahead of the curve...now if somebody would just read my articles. - View all 4 replies
-
Brad Prigmore: And honestly, you probably read the first couple articles and thats it. I am learning certain types of articles make more money..
-
neobliviscar: For comrade idea exchange & fun, I share personal trades. Not those of our Fund. Why write? It will be interesting to see if you are alumnus
-
- View all 0 replies
LATEST REPLIES